Can I read Serum lipoprotein changes following IGF‐I normalization using a growth hormone receptor antagonist in acromegaly on EtoBox?

Serum lipoprotein changes following IGF‐I normalization using a growth hormone receptor antagonist in acromegaly by C. Parkinson; W. M. Drake; G. Wieringa; A. P. Yates; G. M. Besser; P. J. Trainer is a Medicine article available to read on EtoBox.

What is Serum lipoprotein changes following IGF‐I normalization using a growth hormone receptor antagonist in acromegaly about?

## Summary **objective** Active acromegaly is associated with altered lipid metabolism. The purpose of this study was to investigate the effect of serum IGF‐I normalization on serum lipoproteins and insulin, in patients with acromegaly receiving the GH receptor antagonist pegvisomant. **patients** Twenty patients (9 male, mean age 58·7 years, range 28–79) with active acromegaly (baseline serum IGF‐I > 130% the age‐related upper limit of normal) received pegvisomant and achieved a normal serum IGF‐I [585·2 ± 54·3 (mean ± SEM) to 169·2 ± 13·9 ng/ml, __P__ < 0·0001]. **measurements** Total cholesterol (TC), high‐density lipoprotein (HDL) cholesterol, triglyceride (TG), apolipoprotein B (apo B), apolipoprotein A1 (apo A1), lipoprotein a [Lp(a)] and insulin were measured in a single batch analysis on samples obtained at baseline and the first occasion of serum IGF‐I normalization. Low‐density lipoprotein (LDL) was calculated using the Friedewald formula. Paired analysis was performed using Student’s paired __t__‐test and the Wilcoxon signed rank test. **results** Normalization of serum IGF‐I resulted in an increase in TC (5·0 ± 0·3 to 5·7 ± 0·4 mmol/l, __P__ = 0·0068), an increase in LD

Who reads Serum lipoprotein changes following IGF‐I normalization using a growth hormone receptor antagonist in acromegaly?

Author

C. Parkinson; W. M. Drake; G. Wieringa; A. P. Yates; G. M. Besser; P. J. Trainer

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley; Research Square (ISSN 0300-0664)

Published

2002

Language

EN

Field

Medicine (Health Sciences)